Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT02953509 | Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 178 | Gilead SciencesINDUSTRY | 3 |
| May 29, 2025 |
| clinicaltrials |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04892264 | Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | terminated | Phase 1 | 5 | Mayo ClinicOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | terminated | Phase 1 | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT03994705 | Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 20 | Cartesian TherapeuticsINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | terminated | Phase 1 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | terminated | Phase 1 | 22 | Ehab L AtallahOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | terminated | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04464798 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | terminated | Phase 1 | 62 | CelgeneINDUSTRY | 6 | Apr 29, 2025 | clinicaltrials |
| NCT02875223 | A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | terminated | Phase 1 | 75 | CelgeneINDUSTRY | 5 | Apr 20, 2025 | clinicaltrials |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 183 | CelgeneINDUSTRY | 6 | Apr 17, 2025 | clinicaltrials |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04896658 | Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 10 | University of Maryland, BaltimoreOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT05296525 | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL | terminated | Phase 1 / Phase 2 | 13 | Gamida Cell ltdINDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04975399 | Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CelgeneINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT05293912 | SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma. | terminated | Phase 1 | 2 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01997840 | ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 103 | CelgeneINDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT06655818 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM | terminated | Phase 1 / Phase 2 | 4 | GlaxoSmithKlineINDUSTRY | 2 | Mar 3, 2025 | clinicaltrials |
| NCT06210243 | C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 2 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT04150965 | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | terminated | Phase 1 / Phase 2 | 14 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05348889 | First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 7 | Chimagen Biosciences, LtdINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | terminated | Phase 1 / Phase 2 | 13 | Deepa JagadeeshOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | terminated | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05096234 | 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma | terminated | Phase 1 | 2 | Stanford UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | terminated | Phase 1 | 4 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | terminated | Phase 1 | 16 | Lava TherapeuticsINDUSTRY | 4 | Jan 27, 2025 | clinicaltrials |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 29 | Ichnos Sciences SAINDUSTRY | 3 | Jan 17, 2025 | clinicaltrials |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 26 | CRISPR Therapeutics AGINDUSTRY | 4 | Jan 8, 2025 | clinicaltrials |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | terminated | Phase 1 | 49 | CRISPR Therapeutics AGINDUSTRY | 3 | Jan 8, 2025 | clinicaltrials |
| NCT05205161 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | terminated | Phase 1 | 7 | AstraZenecaINDUSTRY | 7 | Jan 7, 2025 | clinicaltrials |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | terminated | Phase 1 | 83 | Seagen Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | terminated | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05350163 | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion | terminated | Phase 1 | 11 | Guenther KoehneOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | terminated | Phase 1 | 60 | Karyopharm Therapeutics IncINDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | terminated | Phase 1 / Phase 2 | 109 | TakedaINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 19 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 9 | Cartesian TherapeuticsINDUSTRY | 2 | Nov 12, 2024 | clinicaltrials |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 16 | iTeos TherapeuticsINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT04860466 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 9 | CelgeneINDUSTRY | 4 | Oct 16, 2024 | clinicaltrials |
Data updated 22 days agoSource updated May 31, 2025source: clinicaltrials